Status:

COMPLETED

Consequence of Lifetime Isolated Growth Hormone Deficiency

Lead Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborating Sponsors:

Genentech, Inc.

Conditions:

Growth Hormone Deficiency

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Growth hormone (GH) deficiency (GHD) in adulthood has been associated with changes in body composition (e.g. increased abdominal obesity, and reduced muscle mass), in organ functions (e.g. reduced car...

Detailed Description

SPECIFIC AIM 1: To study anthropometric parameters, cardiovascular and metabolic status and cardiovascular risk profile, including inflammatory markers of cardiovascular relevance, muscle strength, bo...

Eligibility Criteria

Inclusion

  • Lifetime isolated and untreated growth hormone deficiency

Exclusion

  • Age below 18 years, pregnancy, diabetes

Key Trial Info

Start Date :

September 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2009

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT00149708

Start Date

September 1 2005

End Date

December 1 2009

Last Update

June 15 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Federal University of Sergipe

Aracaju, Sergipe, Brazil, 49060

Consequence of Lifetime Isolated Growth Hormone Deficiency | DecenTrialz